Revvity, Inc. (NYSE:RVTY) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Revvity, Inc. (NYSE:RVTY) have earned a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are presently covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $117.92.

A number of brokerages have commented on RVTY. Jefferies Financial Group began coverage on shares of Revvity in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 price objective for the company. Robert W. Baird lifted their price target on Revvity from $126.00 to $127.00 and gave the company an “outperform” rating in a report on Tuesday, April 30th. Finally, TD Cowen upped their price target on Revvity from $123.00 to $130.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th.

Insider Buying and Selling at Revvity

In related news, insider Joel S. Goldberg sold 4,000 shares of Revvity stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $110.46, for a total value of $441,840.00. Following the completion of the transaction, the insider now owns 36,900 shares in the company, valued at $4,075,974. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Parkside Financial Bank & Trust bought a new position in Revvity in the fourth quarter worth approximately $25,000. Gladius Capital Management LP raised its position in shares of Revvity by 84.1% during the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock valued at $26,000 after buying an additional 106 shares during the period. CENTRAL TRUST Co acquired a new stake in Revvity in the 4th quarter valued at approximately $27,000. Benjamin F. Edwards & Company Inc. acquired a new position in shares of Revvity in the fourth quarter worth $27,000. Finally, ORG Partners LLC acquired a new position in shares of Revvity during the fourth quarter worth $32,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Price Performance

Revvity stock opened at $109.30 on Tuesday. The company’s fifty day moving average price is $106.03 and its 200 day moving average price is $104.69. Revvity has a 1 year low of $79.50 and a 1 year high of $131.96. The stock has a market capitalization of $13.49 billion, a P/E ratio of 90.33, a P/E/G ratio of 2.89 and a beta of 1.08. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.92 and a current ratio of 2.23.

Revvity (NYSE:RVTY) last issued its earnings results on Monday, April 29th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. Revvity had a net margin of 5.49% and a return on equity of 7.37%. The company had revenue of $649.90 million for the quarter, compared to the consensus estimate of $646.83 million. During the same period in the previous year, the firm earned $1.01 earnings per share. Revvity’s quarterly revenue was down 3.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Revvity will post 4.65 earnings per share for the current fiscal year.

Revvity Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, July 19th. This represents a $0.28 annualized dividend and a yield of 0.26%. Revvity’s dividend payout ratio (DPR) is presently 23.14%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.